Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials.

@article{Templeton2013TranslatingCT,
  title={Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials.},
  author={Arnoud J Templeton and Francisco Emilio Vera-Badillo and Linsheng Wang and Mirna Attalla and Paulo de Gouveia and Raya Leibowitz-Amit and Jennifer J. Knox and Malcolm Moore and Srikala S. Sridhar and Anthony Michael Joshua and Gregory R. Pond and Eskandarloo Amir and Ian F. Tannock},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2013},
  volume={24 12},
  pages={
          2972-7
        }
}
BACKGROUND Multiple factors can influence outcomes of patients receiving identical interventions in clinical trials and in routine practice. Here, we compare outcomes of men with metastatic castrate-resistant prostate cancer (mCRPC) treated with docetaxel and prednisone in routine practice and in clinical trials. PATIENTS AND METHODS We reviewed patients with mCRPC treated with docetaxel at Princess Margaret Cancer Centre. Primary outcomes were overall survival and PSA response rate… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 36 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 18 REFERENCES

Similar Papers

Loading similar papers…